Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Better-than-expected Alzheimer's disease treatment sales and a quarterly beat not enough to offset below-consensus EPS outlook Biogen Inc.'s stock (BIIB) fell 0.6% early Wednesday, after the biotech ...

Stock analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Biogen in a research ...

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.